Q2
DGX — Q2 2026 Financial Report Analysis
Quest Diagnostics grew Q2 2026 revenue 10.2% to $3.04B as new Corewell Health and Fresenius work lifted requisitions 13.1%, but lower-priced routine tests cut revenue per requisition 2.8% and trimmed margins; adjusted EPS rose 19.1% to $3.12, helped by a $0.10 tax benefit.